Trial · NCT07910292
Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot Study
NCT07910292, Not applicable, Not yet recruiting, Medical University of Silesia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot Study. Trials, record NCT07910292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot Study
- NCT number
- NCT07910292
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Medical University of Silesia
- Conditions
- Healthy Aging, Cognition
- Interventions
- Cannabidiol (CBD), Placebo
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Verbal Episodic Memory - RAVLT Delayed Free Recall | Approximately 120 minutes after administration of CBD or placebo, during each of the two study sessions. | Verbal episodic memory will be assessed using the Rey Auditory Verbal Learning Test (RAVLT). Participants will be presented with a list of 15 unrelated words over five learning trials, followed by an interference list and delayed recall assessments. The outcome measure will be the number of correctly recalled words during the second delayed free recall assessment, approximately 120 minutes after administration of CBD or placebo. Scores range from 0 to 15, with higher scores indicating better memory performance. |
| Secondary | Working Memory - 2-Back Task Accuracy | During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions. | Working memory will be assessed using a computerized visual 2-back task with emotionally neutral stimuli. Participants will indicate whether the currently presented stimulus matches the stimulus presented two positions earlier. Performance will be measured as the percentage of correct responses, ranging from 0% to 100%, with higher scores indicating better working memory performance. |
| Secondary | Attention - 0-Back Task Accuracy | During cognitive testing beginning approximately 120 minutes after administration of CBD or placebo, at each of the two study sessions. | Attention will be assessed using a computerized visual 0-back task with emotionally neutral stimuli. Participants will respond to the presentation of a predefined target stimulus. Performance will be measured as the percentage of correct responses, ranging from 0% to 100%, with higher scores indicating better attention performance. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Delayed Recall Module | Primary outcome | ConductCognition |
| Verbal Learning | Primary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910292
GET https://conductscience.org/api/trials/v1/NCT07910292/registered